Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma

被引:85
|
作者
Miselis, Nathan R. [1 ]
Wu, Zhijin J. [2 ]
Van Rooijen, Nico [3 ]
Kane, Agnes B. [1 ]
机构
[1] Brown Univ, Dept Pathol & Lab Med, Providence, RI 02912 USA
[2] Brown Univ, Ctr Stat Sci, Providence, RI 02912 USA
[3] Free Univ Amsterdam, Dept Mol Cell Biol, Med Ctr, Amsterdam, Netherlands
关键词
D O I
10.1158/1535-7163.MCT-07-0579
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tumors are a mixture of neoplastic and host stromal cells, which establish a microenvironment that contributes to tumor progression. In this study, the contribution of tumor-associated macrophages (TAMs) to tumor growth and metastasis was examined using an orthotopic, immunocompetent murine model of diffuse malignant peritoneal mesothelioma. The expression profile of cytokines and chemokines in solid tumors was consistent with a M2-polarized, TAM-mediated immunosuppressive microenvironment. TAMs were targeted using liposome-encapsulated clodronate (CLIP). Exposure of tumor spheroids to CM-Dil-labeled CLIP in situ confirms targeting of macrophages and not mesothelioma cells. Intraperitoneal (i.p.) delivery of CLIP produced apoptosis in tumor spheroids and solid tumors in contrast to delivery of liposome-encapsulated PBS or PBS. Mice received an i.p. injection of mesothelioma cells with CLIP delivered i.p. every 5 days. This treatment protocol produces a 4-fold reduction in the number of tumors, a 17-fold reduction in the relative tumor burden, and a 5-fold reduction in invasion and metastasis when compared with mice exposed to liposome-encapsulated PBS or PBS. Following transplantation of tumor spheroids and treatment with CLIP, mice showed a 4-fold reduction in the number of tumors and a 15-fold reduction in relative tumor burden. Mice bearing established tumors showed a 2-fold reduction in the number of tumors and relative tumor burden when exposed to half the previous dose of CLIP delivered by repeated i.p. injection. These reductions in tumor burden are statistically significant and identify TAMs as an important host-derived cell that contributes to growth, invasion, and metastasis in diffuse malignant peritoneal mesothelioma.
引用
收藏
页码:788 / 799
页数:12
相关论文
共 50 条
  • [31] Targeting tumor-associated macrophages to combat pancreatic cancer
    Cui, Ran
    Yue, Wen
    Lattime, Edmund C.
    Stein, Mark N.
    Xu, Qing
    Tan, Xiang-Lin
    ONCOTARGET, 2016, 7 (31) : 50735 - 50754
  • [32] Therapeutic targeting of tumor-associated macrophages and microglia in glioblastoma
    Bowman, Robert L.
    Joyce, Johanna A.
    IMMUNOTHERAPY, 2014, 6 (06) : 663 - 666
  • [33] Immunotherapies Targeting Tumor-Associated Macrophages (TAMs) in Cancer
    Li, Mei-Ye
    Ye, Wei
    Luo, Ke-Wang
    PHARMACEUTICS, 2024, 16 (07)
  • [34] A Novel Photodynamic Therapy Targeting Tumor-Associated Macrophages
    Hayashi, Noriyuki
    Kataoka, Hiromi
    Yano, Shigenobu
    Tanaka, Mamoru
    Joh, Takashi
    GASTROENTEROLOGY, 2015, 148 (04) : S949 - S949
  • [35] Targeting the Tumor Microenvironment: A Close Up of Tumor-Associated Macrophages and Neutrophils
    Russo, Massimo
    Nastasi, Claudia
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [36] ACCESSORY CELL-ACTIVITY OF MURINE TUMOR-ASSOCIATED MACROPHAGES
    DOUGHERTY, GJ
    MCBRIDE, WH
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1986, 76 (03) : 541 - 548
  • [37] Tumor-associated macrophages
    Cassetta, Luca
    Pollard, Jeffrey W.
    CURRENT BIOLOGY, 2020, 30 (06) : R246 - R248
  • [38] TUMOR-ASSOCIATED MACROPHAGES
    MANTOVANI, A
    CURRENT OPINION IN IMMUNOLOGY, 1990, 2 (05) : 689 - 692
  • [39] Targeting tumor-associated macrophages in an experimental glioma model with a recombinant immunotoxin to folate receptor β
    Taku Nagai
    Masashi Tanaka
    Yasuhiro Tsuneyoshi
    Baohui Xu
    Sara A. Michie
    Kazuhisa Hasui
    Hirofumi Hirano
    Kazunori Arita
    Takami Matsuyama
    Cancer Immunology, Immunotherapy, 2009, 58 : 1577 - 1586
  • [40] Targeting tumor-associated macrophages in an experimental glioma model with a recombinant immunotoxin to folate receptor β
    Nagai, Taku
    Tanaka, Masashi
    Tsuneyoshi, Yasuhiro
    Xu, Baohui
    Michie, Sara A.
    Hasui, Kazuhisa
    Hirano, Hirofumi
    Arita, Kazunori
    Matsuyama, Takami
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2009, 58 (10) : 1577 - 1586